8-K: Know Labs Stockholders Approve Massive Share Increase and Equity Plan Expansion

Know Labs, Inc. stockholders have approved a significant increase in authorized common stock to 750 million shares, a substantial expansion of its equity incentive plan, and a private placement leading to a potential change of control.

Summary

• Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing shares available for issuance by 48,950,000, bringing the total maximum aggregate number of shares under the plan to 50,000,000, plus up to 189,820 shares from the 2011 Plan.
• Stockholders approved an amendment to the Articles of Incorporation to increase authorized common stock from 7,500,000 shares to 750,000,000 shares.
• Stockholders approved the issuance of shares representing more than 19.99% of common stock outstanding as of June 6, 2025, and the resulting change of control, related to a private placement with Goldeneye 1995 LLC.
• The Special Meeting of Stockholders was reconvened on July 31, 2025, with 5,380,965 shares (56.18% of outstanding Company Stock) represented, constituting a quorum.

Sentiment

Score: 6

Explanation: While the approvals provide strategic flexibility and capital, the significant potential for dilution and a change of control introduces uncertainty for existing shareholders, balancing the positive aspects of securing funding and operational flexibility.

Positives

• Stockholder approval of key proposals indicates strong support for the company's strategic direction and capital-raising efforts.
• The increase in authorized shares provides the company with significant flexibility for future capital raises, strategic transactions, and employee incentives.
• Expansion of the equity incentive plan allows the company to attract and retain talent through stock-based compensation.
• Approval of the private placement facilitates a capital infusion from Goldeneye 1995 LLC, which can support operations and growth initiatives.

Negatives

• The substantial increase in authorized shares from 7.5 million to 750 million (100x) and the approval of a private placement exceeding 19.99% of outstanding common stock could lead to significant dilution for existing shareholders.
• The private placement with Goldeneye 1995 LLC is noted to result in a "change of control," which could alter the company's strategic direction or management.

Risks

• Significant dilution of existing shareholders due to the massive increase in authorized shares and the private placement.
• Potential for a change in corporate control following the private placement with Goldeneye 1995 LLC.
• Future share price volatility due to increased share availability and potential for further issuances.

Future Outlook

The approvals provide Know Labs with the necessary corporate structure and capital-raising flexibility to pursue future strategic initiatives, including potential further equity issuances and the execution of the private placement with Goldeneye 1995 LLC.

Management Comments

• Ronald P. Erickson, Chief Executive Officer, signed the report on behalf of Know Labs, Inc.

Industry Context

The approval of a significant increase in authorized shares and an equity incentive plan expansion is a common corporate action for growth-stage companies seeking flexibility for future financing, mergers and acquisitions, and talent retention in competitive markets. The private placement indicates a strategic partnership or investment, typical for companies looking to secure capital outside of public offerings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to increased authorized shares and the private placement. Potential for a change in corporate control.
• Employees: Benefit from expanded equity incentive plan, allowing for more stock-based compensation.
• Creditors: Potential for improved financial stability if capital raise strengthens the balance sheet.

Next Steps

• Completion of the private placement with Goldeneye 1995 LLC.
• Potential future issuance of common stock under the increased authorization.
• Issuance of equity awards under the expanded 2021 Equity Incentive Plan.

Key Dates

Recommendation

The approvals for increased authorized shares and the equity incentive plan provide Know Labs with crucial flexibility for future growth and talent retention. The private placement secures capital, which is positive for operations. However, the substantial potential for dilution from the massive increase in authorized shares and the private placement, coupled with the explicit mention of a 'change of control,' introduces significant uncertainty and downside risk for existing shareholders. Investors should hold to observe the execution of the private placement and its impact on the company's strategy and share structure before making further investment decisions.

Keywords

Know Labs, KNW, SEC Filing, 8-K, Stockholder Meeting, Authorized Shares, Equity Incentive Plan, Private Placement, Dilution, Corporate Governance, Capital Raise, Change of Control, NYSE American